


TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES

Patent number: WO9800173
Publication date: 1998-01-08
Inventor: ZHAO ZHIYANG (US); TOMASSELLI ALFREDO G (US); KOEPLINGER KENNETH A (US); PETERSON TILLIE (US); SUARATO ANTONINO (IT)
Applicant: UPJOHN CO (US); ZHAO ZHIYANG (US); TOMASSELLI ALFREDO G (US); KOEPLINGER KENNETH A (US); PETERSON TILLIE (US); SUARATO ANTONINO (IT)
Classification:
- **International:** **A61K47/48; A61K47/48; (IPC1-7): A61K47/48**
- **European:** A61K47/48H4
Application number: WO1997US10817 19970701
Priority number(s): US19960022489P 19960703

Also published as:

WO9800173 (A)
EP0909184 (A3)
EP0909184 (A2)
EP0909184 (B1)

Cited documents:

EP0391799
US5294720
WO9530670
WO9411361
WO8807378
more >>

Report a data error he**Abstract of WO9800173**

The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free -NH- which has been derivatized by the attachment of an electrophile containing a moiety such as p-CN- or p-NO₂-pyridinylsulfonyl groups, or p-NO₂- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The precursor is a synthetic intermediate carrying a free -NH- which has been derivatized by the attachment of an electrophile via a sulfonamide bond.

Data supplied from the **esp@cenet** database - Worldwide